Verve Therapeutics has started dosing patients ... in what is thought to be the first test in humans of an experimental CRISPR/Cas9 genome editing technique known as base editing.

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) saw a large growth in short interest during the month of January.As of January 15th, there was short interest totalling 19,100,000 shares ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.72%.

CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $91.10. The firm has a 50-day moving average price of $43.76 and a 200 day moving average price of $47.16.

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says the company is the “pioneer of gene editing” and ...

Try Now>> See the top stocks recommended by analysts >> Read More on CRSP: CRISPR Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...